However, targeting ICAM-1 in ischemic stroke patients is not a viable therapeutic strategy as using anti-ICAM-1 antibody led to worse clinical outcomes in a clinical trial of 625 ischemic stroke patients (90). Here, ICAM1 is linked to ischemic stroke.